Obermatt
See Similar Stocks →

Euroapi

PAR:EAPI · FR0014008VX5
PharmaceuticalsMedium

360

37
Profit price39
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit100
Price/Book89
Return on Capital64
Cash Return on Capital32
Return on Equity42
EBIT Margin50
Gross Profitability38
Accruals88
Owner Earnings Margin20
Sales growth11
Profit growth10
Reinvestment35
Price momentum1
Debt load68
Refinancing98
Debt Payback1
Liquidity36
Analyst ratings1
Opinion Changes50
Price Target Upside11
Market mood11
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Euroapi doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeENXTPA
Founded2020
Employees1,174
Websiteeuroapi.com/en
ISINFR0014008VX5
Last UpdateApr 2, 2026
Indices
CAC All (France)
Themes
Animal FeedCardiovascularOncologyNutraceuticalHealth CareManufacturing

Description

Euroapi S.A. (EUROAPI) is a global player in the pharmaceutical industry, specializing in the production and supply of active pharmaceutical ingredients (APIs) for various therapeutic applications. The company operates with a robust and diverse port…

Analysis

Middle-of-the-road

Euroapi S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
33
2026

All-time high

33

Jun 2026

All-time low

23

Mar 2026

Average rank

28

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
64
—
—
—
Price/Book
89
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
81
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Euroapi with its peers
Cohance Lifesciences
NSI:COHANCE
37
CountryCyprus
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Krka
LJU:KRKG
63
CountrySlovenia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Vetoquinol
PAR:VETO
76
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →